639

Colorectal cancer is a dangerous disease. Surgery, chemotherapy, radiation therapy and immunotherapy play a key role in its treatment. It is also now known to science that there is a link between vitamin D and this disease. Therefore, in this article, along with all the treatments, we will focus mainly on vitamin D.

  • Журнал номиRE-HEALTH
  • Нашр номи2.3-2020
  • Кўришлар сони 639
  • Ўқишлар сони 535
  • Нашр санаси 30-01-2021
  • Мақола тилиIngliz
  • Саҳифалар сони60-66
Калит сўзлар
Русский

Колоректальный рак - опасное заболевание. Хирургия, химиотерапия, лучевая терапия и иммунотерапия играют ключевую роль в ее лечении. В настоящее время науке также известно, что существует связь между витамином D и этим заболеванием. Поэтому в этой статье мы сосредоточимся на витамине D в сочетании со всеми видами лечения. 

English

Colorectal cancer is a dangerous disease. Surgery, chemotherapy, radiation therapy and immunotherapy play a key role in its treatment. It is also now known to science that there is a link between vitamin D and this disease. Therefore, in this article, along with all the treatments, we will focus mainly on vitamin D.

Калит сўзлар
Ўзбек

Kolorektal saraton xavfli kasallik hisoblanadi. Uni davolashda jarrohlik amaliyoti, kimyoterapiya, radiatsion terapiya va immunoterapiya asosiy o'rinni egallaydi. Shuningdek, hozirda vitamin D va bu kasallik orasida bog'liqlik bor ekanligi fanga ma'lum. Shuning uchun, ushbu maqolada barcha davolash usullari bilan birgalikda, asosan D vitaminiga e'tibor qaratamiz. 

№ Ҳавола номи
1 1. Evans, S., Taylor, C., Antoniou, A., Aggarwal, T., Burns, E., Jenkins, J. T., & Miskovic, D. (2020). Implementation of a clinical pathway for the surgical treatment of colorectal cancer during the COVID‐19 pandemic. Colorectal Disease. doi:10.1111/codi.15247.
2 . Cortesi, E., Caponnetto, S., Masi, G., Urbano, F., Mezi, S., Gelibter, A., … Cianni, R. ( 0 0). Efficacy and tolerability of selective internal radiation therapy (SIRT) with Yttrium-90 as consolidation treatment after chemotherapy in metastatic colorectal cancer. Clinical Colorectal Cancer. doi:10.1016/j.clcc.2020.06.008.
3 3. Franko, J., Shi, Q., Goldman, C. D., Pockaj, B. A., Nelson, G. D., Goldberg, R. M., … Sargent, D. J. (2012). Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. Journal of Clinical Oncology, 30(3), 263–267. doi:10.1200/jco.2011.37.1039.
4 4. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.
5 5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
6 6. Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009;27:2848–2854.
7 7. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet. 2008;371:1007– 1016.
8 8. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–825.
9 9. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715– 722.
10 10. Yedibela S, Klein P, Feuchter K, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol. 2006;13:1538–1544.
11 11. Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for metastatic colorectal cancer: Experiences with 159 patients. J Thorac Cardiovasc Surg. 1996;112:867–874.
12 12. Verwaal VJ, Bruin S, Boot H, et al. 8-Year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–2432.
13 13. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–685.
14 14. Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–3762.
15 15. 12. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer. 1989;63:364–367.
16 16. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–1550.
17 17. Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies. Ann Surg. 2006;243:212–222.
18 18. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–363.
19 19. Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol. 2001;8:632–637.
20 20. Helyer LK, Law CH, Butler M, et al. Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol. 2007;14:1264–1271.
21 21. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–3743.
22 22. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124–132.
23 23. Shen, F., Feng, L., Zhu, Y., Tao, D., Xu, J., Peng, R., & Liu, Z. (2020). Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer. Biomaterials, 120190. doi:10.1016/j.biomaterials.2020.120190.
24 24. Boughanem, H., Cabrera-Mulero, A., Hernández-Alonso, P., Clemente-Postigo, M., Casanueva, F. F., Tinahones, F. J., Macias-Gonzalez, M. (2020). Association between variation of circulating 25-OH vitamin D and methylation of secreted frizzled-related protein 2 in colorectal cancer. Clinical Epigenetics, 12(1). doi:10.1186/s13148-020-008759.
25 25. David Corley Gibbs, Mingyang Song, Marjorie L. McCullough, Caroline Y. Um, Roberd M. Bostick, Kana Wu, W. Dana Flanders, Edward Giovannucci, Mazda Jenab, Magritt Brustad, Anne Tjønneland, Aurora Perez-Cornago, Antonia Trichopoulou, Konstantinos K. Tsilidis, Johan Hultdin, Aurelio Barricarte Gurrea, Bas Bueno-de-Mesquita, Yahya Mahamat-Saleh, Tilman ühn, Marc J. Gunter, Elisabete Weiderpass, Veronika Fedirko. ( 0 0). Association of Circulating Vitamin D With Colorectal Cancer Depends on Vitamin D–Binding Protein Isoforms: A Pooled, Nested, Case-Control Study. JNCI Cancer Spectrum. doi: 10.1093/jncics/pkz083.
Кутилмоқда